This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the safety and effectiveness of Depsipeptide as a treatment for patients with relapsed/refratory mutliple myeloma. If patients agree, we will also be testing samples of patients' bone marrow to test which genes, if any, will be affected by depsipeptide. Depsipeptide will be administered at 13mg/m2 over 4 hours on days 1, 8, and 15 through a peripheral IV or central line. Cycles will be repeated every 28 days until disease progression, patient experiences intolerable side effects, or withdraws consent.
Showing the most recent 10 out of 370 publications